Galectin-3 and matrix metalloproteinases 2 and 9 in peripheral blood of gastric cancer patients
Background: High incidence of gastric cancer (GC), its aggressive clinical course, rapid tumor dissemination, low sensitivity to chemotherapy and lack of reliable laboratory diagnostic criteria urgently require a search for the most informative markers associated with key biologic properties of the...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
MONIKI
2023-05-01
|
| Series: | Alʹmanah Kliničeskoj Mediciny |
| Subjects: | |
| Online Access: | https://almclinmed.ru/jour/article/viewFile/1771/1546 |
| _version_ | 1797828678652002304 |
|---|---|
| author | Ekaterina A. Korotkova Elena S. Gershtein Ekaterina V. Samoilova Irina O. Goryacheva Aram P. Petrosyan Natalia N. Zybina Oleg O. Yanushevich Ivan S. Stilidi Nikolay E. Kushlinskii |
| author_facet | Ekaterina A. Korotkova Elena S. Gershtein Ekaterina V. Samoilova Irina O. Goryacheva Aram P. Petrosyan Natalia N. Zybina Oleg O. Yanushevich Ivan S. Stilidi Nikolay E. Kushlinskii |
| author_sort | Ekaterina A. Korotkova |
| collection | DOAJ |
| description | Background: High incidence of gastric cancer (GC), its aggressive clinical course, rapid tumor dissemination, low sensitivity to chemotherapy and lack of reliable laboratory diagnostic criteria urgently require a search for the most informative markers associated with key biologic properties of the tumors.
Aim: Comparative analysis of galectin-3, matrix metalloproteinase (MMP)-2, and MMP-9 levels in peripheral blood of GC patients and healthy donors, assessment of association of these markers with clinical morphological characteristics of the disease, and prognosis of overall and relapse-free survival.
Materials and methods: Sixty (60) primary treatment-nave GC patients (38 men, 22 women) aged 29 to 81 years and 90 healthy donors compatible with their age and sex were included into the study. Galectin-3 was measured in EDTA plasma, MMP-2 and MMP-9 in serum with standard direct enzyme immunoassay kits "Human MMP-2 (total)", "Human MMP-9 (total)", "Human Galectin-3" (RD Systems, USA).
Results: Plasma galectin-3 concentration in the GC patients was significantly higher than in the healthy controls (median 12.9 and 10.6 ng/ml, respectively; p 0.0001). No difference in serum MMP-9 levels between GC patients and control subjects were found, while MMP-2 level in the control group was significantly higher, than in the GC patients (p = 0.039). No association between galectin-3, MMP-2, and MMP-9 blood levels in the GC patients could be identified. In contrast to GC patients, there was a positive correlation of plasma galectin-3 with age in the control group (rs = 0.51, p 0.005). No associations between the biomarkers levels in blood and clinical and morphological characteristics of GC were established, except MMP-9 being higher at Т4а invasion depth as compared to the earlier Т2 level. Marked differences in the overall survival depending on plasma galectin-3 levels were found, with the cut-off level of 12.9 ng/ml: the 5-year overall survival in the patients with low galectin-3 was better, than in those with its higher level (50 and 43%, respectively; however, the difference was non-significant, р 0.1). Both overall and relapse-free survival of the GC patients was higher in those with low ( 212 ng/ml) serum MMP-2: the 5-year overall survival in this group comprised 60% versus 23% in the patients with higher MMP-2 (p = 0.018). The difference in relapse-free survival was non-significant. Serum MMP-9 levels had no significant impact on the survival of GC patients.
Conclusion: The ambiguous data on the clinical role of galectin-3, MMP-2, MMP-9 in GC obtained in this study indicate the necessity of further investigation of their possible utility for the diagnostics and prognosis of treatment results. |
| first_indexed | 2024-04-09T13:08:13Z |
| format | Article |
| id | doaj.art-9e579446db2345808e6179ba9139e706 |
| institution | Directory Open Access Journal |
| issn | 2072-0505 2587-9294 |
| language | Russian |
| last_indexed | 2024-04-09T13:08:13Z |
| publishDate | 2023-05-01 |
| publisher | MONIKI |
| record_format | Article |
| series | Alʹmanah Kliničeskoj Mediciny |
| spelling | doaj.art-9e579446db2345808e6179ba9139e7062023-05-12T10:29:47ZrusMONIKIAlʹmanah Kliničeskoj Mediciny2072-05052587-92942023-05-01511233110.18786/2072-0505-2023-51-001920Galectin-3 and matrix metalloproteinases 2 and 9 in peripheral blood of gastric cancer patientsEkaterina A. Korotkova0https://orcid.org/0000-0002-2509-5232Elena S. Gershtein1https://orcid.org/0000-0002-3321-801XEkaterina V. Samoilova2https://orcid.org/0000-0003-3178-8331Irina O. Goryacheva3https://orcid.org/0000-0001-5522-291XAram P. Petrosyan4https://orcid.org/0000-0002-2149-4236Natalia N. Zybina5https://orcid.org/0000-0002-5422-2878Oleg O. Yanushevich6https://orcid.org/0000-0003-0059-4980Ivan S. Stilidi7https://orcid.org/0000-0002-0493-1166Nikolay E. Kushlinskii8https://orcid.org/0000-0002-3898-4127N.N. Blokhin National Medical Research Center of OncologyN.N. Blokhin National Medical Research Center of OncologyN.N. Blokhin National Medical Research Center of OncologyN.N. Blokhin National Medical Research Center of OncologyN.N. Blokhin National Medical Research Center of OncologyThe Nikiforov Russian Center of Emergency and Radiation MedicineA.I. Yevdokimov Moscow State University of Medicine and DentistryN.N. Blokhin National Medical Research Center of OncologyN.N. Blokhin National Medical Research Center of OncologyBackground: High incidence of gastric cancer (GC), its aggressive clinical course, rapid tumor dissemination, low sensitivity to chemotherapy and lack of reliable laboratory diagnostic criteria urgently require a search for the most informative markers associated with key biologic properties of the tumors. Aim: Comparative analysis of galectin-3, matrix metalloproteinase (MMP)-2, and MMP-9 levels in peripheral blood of GC patients and healthy donors, assessment of association of these markers with clinical morphological characteristics of the disease, and prognosis of overall and relapse-free survival. Materials and methods: Sixty (60) primary treatment-nave GC patients (38 men, 22 women) aged 29 to 81 years and 90 healthy donors compatible with their age and sex were included into the study. Galectin-3 was measured in EDTA plasma, MMP-2 and MMP-9 in serum with standard direct enzyme immunoassay kits "Human MMP-2 (total)", "Human MMP-9 (total)", "Human Galectin-3" (RD Systems, USA). Results: Plasma galectin-3 concentration in the GC patients was significantly higher than in the healthy controls (median 12.9 and 10.6 ng/ml, respectively; p 0.0001). No difference in serum MMP-9 levels between GC patients and control subjects were found, while MMP-2 level in the control group was significantly higher, than in the GC patients (p = 0.039). No association between galectin-3, MMP-2, and MMP-9 blood levels in the GC patients could be identified. In contrast to GC patients, there was a positive correlation of plasma galectin-3 with age in the control group (rs = 0.51, p 0.005). No associations between the biomarkers levels in blood and clinical and morphological characteristics of GC were established, except MMP-9 being higher at Т4а invasion depth as compared to the earlier Т2 level. Marked differences in the overall survival depending on plasma galectin-3 levels were found, with the cut-off level of 12.9 ng/ml: the 5-year overall survival in the patients with low galectin-3 was better, than in those with its higher level (50 and 43%, respectively; however, the difference was non-significant, р 0.1). Both overall and relapse-free survival of the GC patients was higher in those with low ( 212 ng/ml) serum MMP-2: the 5-year overall survival in this group comprised 60% versus 23% in the patients with higher MMP-2 (p = 0.018). The difference in relapse-free survival was non-significant. Serum MMP-9 levels had no significant impact on the survival of GC patients. Conclusion: The ambiguous data on the clinical role of galectin-3, MMP-2, MMP-9 in GC obtained in this study indicate the necessity of further investigation of their possible utility for the diagnostics and prognosis of treatment results.https://almclinmed.ru/jour/article/viewFile/1771/1546gastric cancergalectin-3matrix metalloproteinase 2matrix metalloproteinase 9serumplasma |
| spellingShingle | Ekaterina A. Korotkova Elena S. Gershtein Ekaterina V. Samoilova Irina O. Goryacheva Aram P. Petrosyan Natalia N. Zybina Oleg O. Yanushevich Ivan S. Stilidi Nikolay E. Kushlinskii Galectin-3 and matrix metalloproteinases 2 and 9 in peripheral blood of gastric cancer patients Alʹmanah Kliničeskoj Mediciny gastric cancer galectin-3 matrix metalloproteinase 2 matrix metalloproteinase 9 serum plasma |
| title | Galectin-3 and matrix metalloproteinases 2 and 9 in peripheral blood of gastric cancer patients |
| title_full | Galectin-3 and matrix metalloproteinases 2 and 9 in peripheral blood of gastric cancer patients |
| title_fullStr | Galectin-3 and matrix metalloproteinases 2 and 9 in peripheral blood of gastric cancer patients |
| title_full_unstemmed | Galectin-3 and matrix metalloproteinases 2 and 9 in peripheral blood of gastric cancer patients |
| title_short | Galectin-3 and matrix metalloproteinases 2 and 9 in peripheral blood of gastric cancer patients |
| title_sort | galectin 3 and matrix metalloproteinases 2 and 9 in peripheral blood of gastric cancer patients |
| topic | gastric cancer galectin-3 matrix metalloproteinase 2 matrix metalloproteinase 9 serum plasma |
| url | https://almclinmed.ru/jour/article/viewFile/1771/1546 |
| work_keys_str_mv | AT ekaterinaakorotkova galectin3andmatrixmetalloproteinases2and9inperipheralbloodofgastriccancerpatients AT elenasgershtein galectin3andmatrixmetalloproteinases2and9inperipheralbloodofgastriccancerpatients AT ekaterinavsamoilova galectin3andmatrixmetalloproteinases2and9inperipheralbloodofgastriccancerpatients AT irinaogoryacheva galectin3andmatrixmetalloproteinases2and9inperipheralbloodofgastriccancerpatients AT aramppetrosyan galectin3andmatrixmetalloproteinases2and9inperipheralbloodofgastriccancerpatients AT natalianzybina galectin3andmatrixmetalloproteinases2and9inperipheralbloodofgastriccancerpatients AT olegoyanushevich galectin3andmatrixmetalloproteinases2and9inperipheralbloodofgastriccancerpatients AT ivansstilidi galectin3andmatrixmetalloproteinases2and9inperipheralbloodofgastriccancerpatients AT nikolayekushlinskii galectin3andmatrixmetalloproteinases2and9inperipheralbloodofgastriccancerpatients |